Codexis (NASDAQ:CDXS) Posts Earnings Results, Misses Expectations By $0.09 EPS

Codexis (NASDAQ:CDXS) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.09), Zacks reports. The business had revenue of $21.46 million during the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. Codexis updated its FY 2025 guidance to EPS.

Codexis Stock Performance

NASDAQ CDXS opened at $3.93 on Friday. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The firm’s fifty day moving average price is $4.60 and its two-hundred day moving average price is $3.95. Codexis has a 1 year low of $2.56 and a 1 year high of $6.08. The firm has a market capitalization of $319.82 million, a P/E ratio of -4.52 and a beta of 2.12.

Analysts Set New Price Targets

CDXS has been the topic of a number of research reports. Benchmark reissued a “hold” rating on shares of Codexis in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price target on shares of Codexis in a research report on Friday, November 22nd.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.